Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome

Clinical Nephrology

Volumn 72, Issue 1, 2009, Pages 69-72

  Sawara, Y ^a   Itabashi, M ^a   Kojima, C ^a   Tabata, H ^a   Kamei, D ^a   Kawanishi, K ^a   Moriyama, T ^a   Sugiura, H ^a   Tsukada, M ^a   Takei, T ^a   Ogawa, T ^a   Yoshida, T ^a   Arai, J ^a   Uchida, K ^a   Tsuchiya, K ^a   Nitta, K ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Minimal change nephritic syndrome; Relapse; Remission; Rituximab

Indexed keywords

CYCLOSPORIN A; LOW DENSITY LIPOPROTEIN; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

APHERESIS; ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; KIDNEY BIOPSY; MALE; NEPHROTIC SYNDROME; RELAPSE; REMISSION; REPEATED DRUG DOSE; RETREATMENT; SINGLE DRUG DOSE; ADULT; LIPOID NEPHROSIS; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOLOGIC FACTORS; MALE; NEPHROSIS, LIPOID; RECURRENCE; TREATMENT OUTCOME;

EID: 70349239452     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp72069     Document Type: Article

References (13)

1. Cobo M, Hernández D, Rodriguez C, Pérez-Tamajón L. Successful therapeutic use of rituximab in refrectory membranous glomerulonephritis. Clin Nephrol 2006; 66: 54-57.
2. Collaborative Study Group of Sandimmun In Nephrotic Syndrome. Safety and tolerability of cyclosporine A (Sandimmun) in idiopathic nephrotic syndrome. Clin Nephrol. 1991; 35: 48-60.
3. Cunard R, Kelly CJ. T cells and minimal change disease. JAm Soc Nephrol. 2002; 13: 1409-1411.
4. Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20: "What do B-cells do?" Clin Immunol. 2005; 117: 207-213.
5. François H, Daugas E, Bensman A, Ronco P. Unexpected efficacy of Rituximab in multirelapsing minimal change nephrotic syndrome in the adult: First case report and pathophysiological considerations. Am J Kidney Dis. 2006; 49: 158-161.
6. Hofstra JM, Deegens JK, Wetzels JF. Rituximab: effective treatment for severe steroid-dependent minimal change nephritic syndrome? Nephrol Dial Transplant. 2007; 22: 2100-2102.
7. Inoue Y, Iijima K, Nakamura H, Yoshikawa N. Two year cyclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 1999; 13: 33-38.
8. Kamar N, Faguer S, Esposito L, Guitard J, Nogier MB, Durand D, Rostaing L. Treatment of focal segmental glomerulosclerosis with rituximab: two case reports. Clin Nephrol 2997; 67: 250-254.
9. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R. IDEC-C2B8 (Rituximab) anti-CD20 mono-clonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997; 90: 2188-2195.
10. Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Miki S, Kuwahara T, Takamitsu Y, Takemura T, Tsubakihara Y. Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group. Kidney Int. 1999; 71 (Suppl): S122-S125.
11. Naito M, Takei T, Eguchi A, Uchida K, Tsuchiya K, Nitta K. Monitoring of blood cyclosporine concentration in steroid-resistant nephritic syndrome. Intern Med. 2008; 47: 1567-1572.
12. Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F. CD20: A target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev. 2005; 4: 526-531.
13. Takei T, Koike M, Suzuki K, Shirota S, Itabashi M, Ohtsubo S, Sugiura H, Suzuki K, Kojima C, Takahashi M, Ino J, Ogawa T, Uchida K, Tsuchiya K, Yumura W, Nitta K. The characteristics of relapse in adult-onset minimal-change nephrotic syndrome. Clin Exp Nephrol. 2007; 11: 214-217.